Tag: Genetically Defined Diseases
-
Cogent Biosciences Submits New Drug Application to Advance Precision Therapies
Cogent Biosciences Submits New Drug Application to Regulatory Authorities Cogent Biosciences, Inc., a Waltham, Massachusetts and Boulder, Colorado-based biotechnology company focused on precision therapies for genetically defined diseases, announced on December 30, 2025, that it has submitted a New Drug Application (NDA) for its lead therapy. The submission marks a pivotal milestone for the company…
-
Cogent Biosciences Submits New Drug Application for Genetic Diseases
Cogent Biosciences Announces Submission of New Drug Cogent Biosciences, Inc., a biotechnology company focused on precision therapies for genetically defined diseases, announced today that it has submitted its New Drug submission to the relevant regulatory authorities. This milestone marks a key phase in the company’s effort to bring targeted, mechanism-based treatments to patients who currently…
-
Cogent Biosciences Submits New Drug Application to FDA
Cogent Biosciences Advances Precision Medicine with New Drug Application Submission Cogent Biosciences, a biotechnology company dedicated to developing precision therapies for genetically defined diseases, announced today that it has submitted a key regulatory document for its latest therapeutic candidate. The submission marks a significant milestone in Cogent’s mission to bring targeted treatments to patients who…